Notification of transaction

Hikma Pharmaceuticals Plc
21 January 2008


                    Notification of transaction by Directors

LONDON, 21 January 2008 - Hikma Pharmaceuticals PLC (the 'Company') (LSE: HIK)
(DIFX:HIK) announces that the Directors of the Company listed below, and Darhold
Limited, being a connected person for the purposes of the Listing Rules,
notified the Company on 17 January 2008, that they had undertaken the following
subscriptions of shares as part of the of the placing undertaken by the Company
on that date:


Name             Shares           Percentage of enlarged issued share    Price
                 subscribed       capital
Darhold           5,233,056       2.783                                480 pence
Limited
Samih Darwazah      168,944       0.09                                 480 pence
Said Darwazah        60,665       0.032                                480 pence
Mazen Darwazah       55,633       0.03                                 480 pence


Following the notification, each of the Directors and Darhold Limited have the
following holdings of ordinary shares of 10 pence each in the capital of the
Company representing the percentages of the enlarged issued ordinary share
capital of the Company set out below.

Name                No. Of Ordinary                Percentage of enlarged issued 
                            Shares                                 share capital
Darhold                 57,883,028                                  30.783
Limited
Samih Darwazah           1,875,450                                  0.997
Said Darwazah              673,445                                  0.358
Mazen Darwazah             617,591                                  0.328

Each of the above individuals is both a director and a Person Discharging
Managerial Responsibility in respect of the Company. Darhold Limited is
connected with the above directors for the purposes of the Listing Rules. The
above notification relates to DTR 3.1.4R(1)(a) and other Listing Rules.


                                   -- ENDS --



Enquiries:

Hikma Pharmaceuticals PLC
Henry Knowles                                     [phone]
Company Secretary
Susan Ringdal                                     [phone]
Investor Relations Director

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed          [phone]


About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'.
Hikma's operations are based principally in the Middle East and North Africa
('MENA') region, where it is a market leader and sells across 17 countries, the
United States and Europe. In 2006, the Group achieved revenues of $317 million
(2005 $262 million) and profit attributable to shareholders was $55 million
(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. For
news and other information, please visit www.hikma.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange